Previous 10 | Next 10 |
Icon (ICLR): Q1 Non-GAAP EPS of $2.06 beats by $0.09; GAAP EPS of $1.82 misses by $0.14.Revenue of $858.2M (+20.0% Y/Y) beats by $68.83M.Standalone full year 2021 revenue guidance increased from a range of $3,200 - $3,300 million to a range of $3,400 - $3,500 million, representing a year over...
Highlights Record net business wins in the quarter of $1,100 million, an increase of 27% year on year; a net book to bill of 1.28. Record closing backlog of $10 billion, an increase of 14.0% year on year. Quarter 1 reported revenue of $858.2 million representin...
Solid biopharma demand, rising diagnostic trends, and the economic recovery will support a ‘healthy’ Q1 revenue growth argues UBS analyst Dan Brennan and the team in a Q1 2021 preview written on the sector of life sciences & diagnostic tools.The firm picks IQVIA Holdings ([[...
An influx of news into healthcare's contract research organization sector is calling for a re-rating, Baird says in looking at its preferred picks headed into Q1 earnings. First came an activist stake in Laboratory Corp. of America (LH) to press for strategic alternatives. That was followed b...
Merger activity increased last week with six new deals announced. $50 billion worth of deals announced in a single week. Thermo Fisher Scientific to acquire PPD Inc. For further details see: Merger Arbitrage Mondays - Microsoft's Acquisition Of Nuance Offers A 5% Spread ...
Icon plc (ICLR) said it won HSR approval for its planned purchase of PRA Health (PRAH).Icon confirmed winning regulatory approval for the PRA deal in an email to Seeking Alpha. The HSR deadline expired for the deal expired yesterday.Earlier today Icon peer PPD (PPD) agreed to a sale of the co...
Syneos Health (SYNH) rose 5.2% following Thermo's Fisher (TMO) planned acquisition of PPD Inc. (PPD)Syneos Health is a per of PPD and in May Reuters reported that the contract research organization was exploring a sale.Other CRO Charles River Labs (CRL) rose 2.5%, while La...
ICON PLC is a Contract Research Organization that generated revenues of $2.8bn in FY20, and whose share price is +173% over a five-year period. Having potentially reached its rapid growth ceiling, the company has taken the decision to acquire its closest-matched sector rival PRA Healt...
Wells Fargo analyst Dan Leonard has upgraded shares of clinical research organization ICON plc (ICLR) from equal weight to overweight and is bumping up his price target to $235 from $200.Based on yesterday's closing price, that represents upside of ~20%.Leonard's bullishness is based on the c...
Gilead Sciences (GILD) is trading ~1.6% higher in the pre-market after Bernstein upgraded the stock to outperform from market perform.The analyst Aaron Gal expects that company to generate future catalysts and growth drivers the lack of which led the stock to remain undervalued in the pa...
News, Short Squeeze, Breakout and More Instantly...
ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2024 with a number of leading business and industry awards recognising the company’s leadership position in the clinical research industry, in addi...
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the second quarter 2024 after the market closes on Wednesday, July 24, 2024. The company will hold a conference call and webcas...
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 1:30pm ET. Any changes to this event and links...